CD99 Immunoreactivity in Atypical Fibroxanthoma
Open Access
- 1 January 2002
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 117 (1), 126-131
- https://doi.org/10.1309/2exb-70cw-3u6p-vq6h
Abstract
Atypical fibroxanthoma (AFX), a pleomorphic superficial cutaneous tumor of low-grade malignancy, shares many morphologic features with malignant melanoma (MM) and squamous cell carcinoma (SCC). Absence of S-100, keratin, and desmin immunoreactivity is the clue for this diagnosis. In a search for positive markers, we tested 26 cases of AFX with 2 antibodies: O13 (CD99) and protein gene product 9.5 (PGP9.5). We also included 10 cases of poorly differentiated SCC and 10 cases of MM in the study. In AFX, CD99 immunoreactivity was present in 19 cases (73%), whereas focal PGP9.5 immunoreactivity was found in only 9 cases (35%). None of the SCC cases showed CD99 immunostaining. No CD99 immunoreactivity was found in 9 of 10 cases of MM. To our knowledge, this is the first report of CD99 and PGP9.5 immunostaining in AFX. We believe, based on our results, that CD99 may be a helpful “positive” feature in the histopathologic diagnosis of AFX.Keywords
This publication has 20 references indexed in Scilit:
- Giant Cell Atypical Fibroxanthoma: Does it Really Exist?The American Journal of Dermatopathology, 1999
- Synovial sarcomaAnnals of Diagnostic Pathology, 1998
- Cellular ‘neurothekeoma’: an epithelioid variant of dermatofibroma?Histopathology, 1998
- Immunohistochemical Profile of Monoclonal Antibody 013The American Journal of Surgical Pathology, 1994
- The spectrum of fibrohistiocytic tumours with special emphasis on malignant fibrous histiocytomaCurrent Diagnostic Pathology, 1994
- Atypical FibroxanthomaThe American Journal of Surgical Pathology, 1993
- Cellular Neurothekeoma A Distinctive Variant of Neurothekeoma Mimicking Nevomelanocytic TumorsThe American Journal of Surgical Pathology, 1990
- Immunostaining in Atypical Fibroxanthoma of the SkinPathology - Research and Practice, 1988
- Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions.Journal of Clinical Pathology, 1984
- Leiomyosarcoma of the skin and subcutaneous tissueCancer, 1981